ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -65.14% | 32.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -65.14% | 32.06% | |||
| Cost of Revenue | 4.91% | 13.51% | |||
| Gross Profit | -11.90% | -11.95% | |||
| SG&A Expenses | 5.06% | 1.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.94% | 11.02% | |||
| Operating Income | -10.48% | -9.64% | |||
| Income Before Tax | -13.64% | -14.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.64% | -14.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.64% | -14.93% | |||
| EBIT | -10.48% | -9.64% | |||
| EBITDA | -10.57% | -9.68% | |||
| EPS Basic | -13.59% | -15.60% | |||
| Normalized Basic EPS | -13.59% | -15.60% | |||
| EPS Diluted | -13.59% | -15.60% | |||
| Normalized Diluted EPS | -13.59% | -15.60% | |||
| Average Basic Shares Outstanding | 0.04% | -0.58% | |||
| Average Diluted Shares Outstanding | 0.04% | -0.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||